comparemela.com

Page 19 - Aptorum Group Limited News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aptorum Group Limited Interview to Air on Bloomberg U S on the RedChip Money Report®

Regulatory News: Aptorum Group Limited , a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview. | April 22, 2022

United statesDarren luiAptorum group formDaptorum groupAptorum group orTechnologies pte ltdAptorum group limited nasdaqSingapore agency for scienceRegulatory newsGroup limitedEuronext parisRedchip money reportAccelerate technologies pte ltdAptorum group limitedSecurities litigation reform actFrench autorit

Aptorum Group: Advancing Disease Therapies (NASDAQ:APM)

Aptorum Group is advancing therapeutic programs to serve unmet needs in several areas. Read more to find out why I'm not buying APM stock.

United statesHong kongUnited kingdomSiemens digitalvisionTechnologies pte ltdDrug administrationSingapore agency for scienceTrademark officeMedicines coAptorum innovations holdingAptorum group limitedAmerican cancer societyOrphan drug designationUnited therapeuticsMethicillin resistant staphylococcus aureusAccelerate technologies pte ltd

Aptorum Group Limited: Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce that the United States

United statesDarren luiGhislaine gasparettoAptorum group formAptorum group orTechnologies pte ltdInvestor relations departmentDrug administrationSingapore agency for scienceActifin financial communications europeRedchip financial communications united statesDaptorum groupAptorum group limited nasdaqAmerican cancer societyRegulatory newsGroup limited

Aptorum Group Limited: Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and

Darren luiGhislaine gasparettoAptorum group formAptorum group orTechnologies pte ltdInvestor relations departmentSingapore agency for scienceActifin financial communications europeRedchip financial communications united statesDaptorum groupTrademark officeAptorum group limited nasdaqRegulatory newsGroup limitedEuronext parisExecutive director

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting

Hong kongCayman islandsDouglas arnerDarren luiClark chengCharles bathurstGhislaine gasparettoIan huenMirko schererJustin wuAptorum group formAptorum group orTechnologies pte ltdArticles of associationInvestor relations departmentSingapore agency for science

vimarsana © 2020. All Rights Reserved.